Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul-Aug;4(4):458-65.
doi: 10.4161/mabs.20230. Epub 2012 Jul 1.

Brentuximab vedotin

Niels W C J van de Donk  1 , Eugen Dhimolea
Affiliations
Review

Brentuximab vedotin

Niels W C J van de Donk et al. MAbs. 2012 Jul-Aug.

Abstract

Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Following binding to CD30, brentuximab vedotin is rapidly internalized and transported to lysosomes where MMAE is released and binds to tubulin, leading to cell cycle arrest and apoptosis. Several trials have shown durable antitumor activity with a manageable safety profile in patients with relapsed/refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or primary cutaneous CD30-positive lymphoproliferative disorders. Peripheral sensory neuropathy is a significant adverse event associated with brentuximab vedotin administration. Neuropathy symptoms are cumulative and dose-related. Multiple ongoing trials are currently evaluating brentuximab vedotin alone or in combination with other agents in relapsed/refractory patients, as well as patients with newly diagnosed disease.

PubMed Disclaimer

Figures

None
Figure 1. Classical Hodgkin lymphoma of the nodular sclerosis type. (A) Hematoxylin and eosin (H&E) staining. (B) The Reed-Sternberg cells positively stained for CD30.
None
Figure 2. Systemic anaplastic large cell lymphoma. (A) Hematoxylin and eosin (H&E) staining showing large pleomorphic tumor cells with an intrasinusoidal growth pattern and (B) homogeneous expression of CD30.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349–60. doi: 10.1016/0092-8674(93)90361-S. - DOI - PubMed
    1. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17:1535–42. - PMC - PubMed
    1. Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci U S A. 1996;93:14053–8. doi: 10.1073/pnas.93.24.14053. - DOI - PMC - PubMed
    1. Harlin H, Podack E, Boothby M, Alegre ML. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol. 2002;169:2451–9. - PubMed
    1. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol. 2000;156:1723–31. doi: 10.1016/S0002-9440(10)65043-2. - DOI - PMC - PubMed

Publication types

MeSH terms